Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 6/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.44 |
| ▸ | SRC | P12931 | 7/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 2/20 | 0.42 |
| ▸ | YES1 | P07947 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | NEK2 | P51955 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL141995 | 0.82 | RET (0.61) | AURKAKDRPDGFRBFGFR1SRC | |
| SCHEMBL6266758 | 0.81 | AURKA (0.36) | AURKA | |
| SCHEMBL6514860 | 0.80 | AKT2 (0.58) | AURKAKDRPDGFRBFGFR1SRC | |
| SCHEMBL6519857 | 0.79 | AURKA (0.56) | AURKAKDRPDGFRBFGFR1SRC | |
| SCHEMBL143571 | 0.78 | ALK (0.63) | AURKAKDRPDGFRBFGFR1SRC | |
| SCHEMBL6333460 | 0.78 | AURKA (0.53) | AURKAKDRPDGFRBFGFR1SRC | |
| SCHEMBL144702 | 0.77 | PDGFRB (0.76) | AURKAKDRPDGFRBFGFR1SRC | |
| SCHEMBL144133 | 0.77 | KDR (0.63) | AURKAKDRPDGFRBFGFR1SRC | |
| SCHEMBL144707 | 0.76 | AURKA (0.53) | AURKAKDRPDGFRBFGFR1SRC | |
| SCHEMBL147260 | 0.75 | FGFR1 (0.76) | AURKAKDRPDGFRBFGFR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | AURKA 4579/4885KDR 1077/4885PDGFRB 467/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | AURKA 4579/4885KDR 1077/4885PDGFRB 467/4885 |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | DMPK, ADK, MAP3K20 | AURKA 273/4885KDR 398/4885PDGFRB 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.